UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
(Rule 14a-101)
INFORMATION REQUIRED IN
PROXY STATEMENT
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant To Section 14(a) of the
Securities Exchange Act of 1934
Filed by the Registrant x Filed by a Party other than the Registrant ¨
Check the appropriate box:
| ¨ | Preliminary Proxy Statement | |
| ¨ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) | |
| ¨ | Definitive Proxy Statement | |
| x | Definitive Additional Materials | |
| ¨ | Soliciting Material Pursuant to § 240.14a-12 | |
Juniper Pharmaceuticals, Inc.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the Appropriate Box):
| x | No fee required. | |||
| ¨ | Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. | |||
| (1) | Title of each class of securities to which transaction applies:
| |||
| (2) | Aggregate number of securities to which transaction applies:
| |||
| (3) | Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
| |||
| (4) | Proposed maximum aggregate value of transaction:
| |||
| (5) | Total fee paid:
| |||
| ¨ | Fee paid previously with preliminary materials. | |||
| ¨ | Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. | |||
| (1) | Amount Previously Paid:
| |||
| (2) | Form, Schedule or Registration Statement No.:
| |||
| (3) | Filing Party:
| |||
| (4) | Date Filed:
| |||
Dear Fellow Stockholders,
You recently received proxy materials in connection with the 2015 Annual Meeting of Stockholders of Juniper Pharmaceuticals, Inc. (formerly known as Columbia Laboratories, Inc.) scheduled to be held on July 7th, 2015.
In addition to the election of directors and the ratification of our independent registered public accounting firm, you are being asked to approve the 2015 Long-Term Incentive Plan and, on an advisory basis, the compensation of our named executive officers, or “say-on-pay.”
Your board of directors unanimously recommends that you vote “FOR” each of the three proposals.
According to our latest records,YOURPROXYVOTE HASNOT YETBEENRECEIVED.
Your vote is important.Please vote today by telephone or Internet to ensure your vote is received in time for the meeting! It is quick and easy.
TOVOTETHROUGHTHEINTERNET: | TOVOTEBYTOUCHTONEPHONE: | |
Go towww.proxyvote.com and follow the instructions on the website to vote your shares using the 12-digit control number on the enclosed voting instruction form. | Call the toll-free number on the enclosed voting instruction form and follow the instructions. |
Alternatively, you may sign the enclosed voting instruction form and return it in the postage-paid envelope provided.
If you have any questions, please do not hesitate to call our proxy solicitation firm, MacKenzie Partners at 800.322.2885 (toll-free in N. America) or at 212.929.5500.
Thank you in advance for your support and for acting promptly.
On behalf of your Board of Directors,
/s/ Frank Condella
Frank Condella
CEO Juniper Pharmaceuticals
